Finance

Lists
KLBF:IDX
Kalbe Farma Tbk PT
IDR 780,00
+1,96%
(+15,00) 1D
13 ຕ.ລ., 16 ໂມງ 12 ນາທີ 15 ວິນາທີ GMT+7  ·   IDR
All symbols
SymbolPriceChange% Change
Generating top insights for KLBF...
Open
IDR 770
High
IDR 780
Low
IDR 755
Mkt. cap
36,51ລລ
Avg. vol.
66,50 ລ້ານ
Volume
37,55 ລ້ານ
Dividend
2,56%
Quarterly dividend
IDR 5
Ex-dividend date
4 ມິ.ຖ. 2026
P/E ratio
9,80
52-wk high
IDR 1.345
52-wk low
IDR 630
EPS
IDR 80
Shares outstanding
46,81 ຕື້
No. of employees
13 ພັນ
Open
IDR 770
High
IDR 780
Low
IDR 755
Mkt. cap
36,51ລລ
Avg. vol.
66,50 ລ້ານ
Volume
37,55 ລ້ານ
Dividend
2,56%
Quarterly dividend
IDR 5
Ex-dividend date
4 ມິ.ຖ. 2026
P/E ratio
9,80
52-wk high
IDR 1.345
52-wk low
IDR 630
EPS
IDR 80
Shares outstanding
46,81 ຕື້
No. of employees
13 ພັນ
News stories
From web sources and news partners
Profile
PT Kalbe Farma Tbk, or simply known as Kalbe, is an Indonesian pharmaceutical, healthcare and nutrition company established in 1966. The company has expanded by strategic acquisitions of pharmaceutical companies, becoming an integrated consumer health and nutrition enterprise. The Kalbe Group has brands in the prescription drugs, OTC drugs, energy drink and nutrition products, with a distribution arm that reaches over one million outlets. Notably, the company produces misoprostol, a drug which is used to treat stomach ulcers but is also widely used in Indonesia as an illegal abortifacient. Company brands in healthcare and pharmaceutical segments include Promag, Mixagrip, Woods, Komix, Diabetasol, Prenagen, Extra Joss and Fitbar. Kalbe is the largest publicly listed pharmaceutical company in Southeast Asia with around US$5 billion in market capitalization and revenues of over Rp 15 trillion. The name "Kalbe" is a syllabic abbreviation of its founder's name: Khouw Lip Boen. Wikipedia
About Kalbe Farma Tbk PT
CEO-
Employees12,8 ພັນ
Founded10 ກ.ຍ. 1966
Headquarters-
SectorPharmaceutical industry
Last report
28 ກ.ລ. 2026
Fiscal period
Q2 2026
IDR 19,68 / IDR 20,14
-2,28%miss
Revenue / Est. (IDR)
9,80 ລ້ານລ້ານ / -
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in IDR
Loading Previous Earnings...
Revenue
Net income
All values in IDR
ກ.ຍ. 2025
ທ.ວ. 2025
ມ.ນ. 2026
ມິ.ຖ. 2026
Revenue
8,91 ລ້ານລ້ານ
9,34 ລ້ານລ້ານ
9,68 ລ້ານລ້ານ
9,80 ລ້ານລ້ານ
Cost of goods sold
5,46 ລ້ານລ້ານ
5,92 ລ້ານລ້ານ
6,02 ລ້ານລ້ານ
6,25 ລ້ານລ້ານ
Cost of revenue
5,46 ລ້ານລ້ານ
5,92 ລ້ານລ້ານ
6,02 ລ້ານລ້ານ
6,25 ລ້ານລ້ານ
Research and development expenses
98,31 ຕື້
160,88 ຕື້
113,14 ຕື້
122,60 ຕື້
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2,51 ລ້ານລ້ານ
1,95 ລ້ານລ້ານ
2,23 ລ້ານລ້ານ
2,27 ລ້ານລ້ານ
Operating expense
2,60 ລ້ານລ້ານ
2,14 ລ້ານລ້ານ
2,33 ລ້ານລ້ານ
2,39 ລ້ານລ້ານ
Total operating expenses
8,06 ລ້ານລ້ານ
8,05 ລ້ານລ້ານ
8,36 ລ້ານລ້ານ
8,64 ລ້ານລ້ານ
Operating income
851,77 ຕື້
1,28 ລ້ານລ້ານ
1,32 ລ້ານລ້ານ
1,16 ລ້ານລ້ານ
Other non operating income
-3,78 ຕື້
-4,17 ຕື້
-3,63 ຕື້
-3,74 ຕື້
EBT including unusual items
877,87 ຕື້
1,30 ລ້ານລ້ານ
1,36 ລ້ານລ້ານ
1,19 ລ້ານລ້ານ
EBT excluding unusual items
888,55 ຕື້
1,30 ລ້ານລ້ານ
1,36 ລ້ານລ້ານ
1,18 ລ້ານລ້ານ
Income tax expense
211,19 ຕື້
252,81 ຕື້
303,84 ຕື້
271,57 ຕື້
Effective tax rate
24,06%
19,41%
22,40%
22,80%
Other operating expenses
-7,23 ຕື້
31,35 ຕື້
-10,02 ຕື້
2,13 ຕື້
Net income
656,41 ຕື້
1,03 ລ້ານລ້ານ
1,03 ລ້ານລ້ານ
890,54 ຕື້
Net profit margin
7,37%
11,07%
10,63%
9,09%
Earnings per share
14,44
22,72
22,74
19,68
Interest and investment income
41,31 ຕື້
40,43 ຕື້
32,07 ຕື້
43,61 ຕື້
Interest expense
-9,69 ຕື້
-5,77 ຕື້
-4,61 ຕື້
-6,78 ຕື້
Net interest expenses
31,62 ຕື້
34,66 ຕື້
27,46 ຕື້
36,83 ຕື້
Depreciation and amortization charges
-
-
-
-
EBITDA
1,05 ລ້ານລ້ານ
1,45 ລ້ານລ້ານ
1,51 ລ້ານລ້ານ
1,20 ລ້ານລ້ານ
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
ແອັບຂອງ Google